NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT04759911 2025-11-13Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerM.D. Anderson Cancer CenterPhase 2 Active not recruiting30 enrolled
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT07010393 2025-06-08Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyFujian Medical UniversityPhase 4 Not yet recruiting335 enrolled
NCT04280081 2025-04-20LIBRETTO-321Eli Lilly and CompanyPhase 2 Active not recruiting77 enrolled 13 charts
NCT05668962 2024-12-12Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCMassachusetts General HospitalPhase 2 Recruiting30 enrolled